Conclusion: While targeted therapies for the RAS/RAF/MEK/ERK and PI3K/Akt pathways have advanced BC treatment, addressing challenges such as resistance, toxicity, and tumor heterogeneity is critical. This evidence concerns the gene PIK3CA and neoplasm.